KalVista Pharmaceuticals (KALV) Cash from Operations Growth (3y) (2019 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 37.40% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 20.11% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 16.64% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -7.60% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 34.32% |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | -33.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -33.82% |
| Apr 30, 2025 | -14.64% |
| Oct 31, 2024 | -26.58% |
| Jul 31, 2024 | -31.38% |
| Apr 30, 2024 | -11.00% |
| Jan 31, 2024 | -53.75% |
| Oct 31, 2023 | -35.60% |
| Jul 31, 2023 | -95.31% |
| Apr 30, 2023 | -21.51% |
| Jan 31, 2023 | 10.85% |
| Oct 31, 2022 | -38.13% |
| Jul 31, 2022 | -26.35% |
| Apr 30, 2022 | -36.60% |
| Jan 31, 2022 | -9.02% |
| Oct 31, 2021 | -30.54% |
| Jul 31, 2021 | -41.86% |
| Apr 30, 2021 | -22.86% |
| Jan 31, 2021 | -31.40% |
| Oct 31, 2020 | -3.09% |
| Jul 31, 2020 | 6.91% |
| Apr 30, 2020 | -68.43% |
| Jan 31, 2020 | -5.26% |
| Oct 31, 2019 | -23.13% |
| Jul 31, 2019 | -25.87% |